

Title (en)  
USE OF BETA-MANNOSYLGLYCERATE AND DERIVATIVES IN COSMETIC AND DERMATOLOGICAL FORMULATIONS

Title (de)  
VERWENDUNG VON BETA-MANNOSYLGLYCERAT UND DERIVATEN IN KOSMETISCHEN UND DERMATOLOGISCHEN FORMULIERUNGEN

Title (fr)  
UTILISATION DE  $\beta$ -MANNOSYLGLYCERATE ET DE SES DERIVES DANS DES FORMULATIONS COSMETIQUES ET DERMATOLOGIQUES

Publication  
**EP 1311236 A1 20030521 (DE)**

Application  
**EP 01969596 A 20010816**

Priority

- DE 10040933 A 20000818
- EP 0109445 W 20010816

Abstract (en)  
[origin: WO0215867A1] The invention relates to the incorporation of the low-molecular substance (compatible solute) ss-mannosylglycerate (firoin) extracted from extremophilic micro-organisms and/or of derivatives of this compound, e.g. an acid, a salt or ester, in particular, also of the ss-mannosylglyceramide (firoin-A) in cosmetic or dermatological formulations for protecting skin from environmental influences and for improving the regenerability of the skin. Firoins (ss-mannosylglycerate and ss-mannosylglyceramide) are, according to the invention, involved in the active cell protection of the cell-specific free-radical scavengers, of the proteins, of the antioxidants, of the DNA, of the cell membranes and of other cell constituents by virtue of the fact that they protect (thermally, chemically and physically) these against damaging environmental influences, e.g. UV radiation, IR radiation and environmental stress. For other active substances added to the cosmetic formulation, firoins can serve as co-solvents and penetration intensifiers in order to not only stabilize these in the cosmetic formulation but also to actively transport them into deeper skin layers.

IPC 1-7  
**A61K 7/48**; **A61K 31/70**; **A61P 17/00**

IPC 8 full level  
**C07H 15/04** (2006.01); **A61K 8/00** (2006.01); **A61K 8/34** (2006.01); **A61K 8/36** (2006.01); **A61K 8/365** (2006.01); **A61K 8/368** (2006.01); **A61K 8/49** (2006.01); **A61K 8/60** (2006.01); **A61K 8/66** (2006.01); **A61K 8/67** (2006.01); **A61K 8/96** (2006.01); **A61K 31/7032** (2006.01); **A61P 17/00** (2006.01); **A61P 17/16** (2006.01); **A61P 25/18** (2006.01); **A61P 31/12** (2006.01); **A61P 37/04** (2006.01); **A61P 39/06** (2006.01); **A61Q 1/00** (2006.01); **A61Q 1/04** (2006.01); **A61Q 1/10** (2006.01); **A61Q 1/12** (2006.01); **A61Q 17/00** (2006.01); **A61Q 17/04** (2006.01); **A61Q 19/00** (2006.01)

CPC (source: EP US)  
**A61K 8/498** (2013.01 - EP US); **A61K 8/60** (2013.01 - EP US); **A61P 17/00** (2017.12 - EP); **A61P 17/16** (2017.12 - EP); **A61P 25/18** (2017.12 - EP); **A61P 31/12** (2017.12 - EP); **A61P 37/04** (2017.12 - EP); **A61P 39/06** (2017.12 - EP); **A61Q 17/04** (2013.01 - EP US)

Citation (search report)  
See references of WO 0215867A1

Designated contracting state (EPC)  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)  
**WO 0215867 A1 20020228**; AU 8980601 A 20020304; DE 10040933 A1 20020307; EP 1311236 A1 20030521; JP 2004506675 A 20040304; US 2005100534 A1 20050512

DOCDB simple family (application)  
**EP 0109445 W 20010816**; AU 8980601 A 20010816; DE 10040933 A 20000818; EP 01969596 A 20010816; JP 2002520777 A 20010816; US 34497103 A 20030630